Administering the hepatitis B vaccine at birth is a cornerstone of global public-health strategy because it prevents a lifelong, incurable viral infection at the moment infants are most vulnerable and least likely to be diagnosed. The rationale is grounded in virology, epidemiology, and the unique biology of newborn immunity. Hepatitis B virus (HBV) is transmitted through blood and bodily fluids, and one of the most efficient routes of transmission is perinatal exposure from an infected mother during delivery. Even mothers who test negative early in pregnancy can acquire infection later, and screening is inconsistent, making universal at-birth vaccination the only reliable safeguard. Newborns who contract HBV have a ninety percent risk of progressing to chronic hepatitis B because their immature immune systems cannot mount an effective clearance response; by contrast, adults who acquire HBV clear it spontaneously in the vast majority of cases. Chronic infection can silently persist for decades, eventually causing cirrhosis, liver failure, and hepatocellular (liver) carcinoma.

The first dose of the hepatitis B vaccine given within twenty-four hours of birth functions as post-exposure prophylaxis to neutralize the virus before it can establish infection, especially when paired with hepatitis B immunoglobulin for infants of known infected mothers. The vaccine triggers early antibody formation and primes the adaptive immune system during a critical window when mucosal micro-abrasions and maternal blood exposure are unavoidable. Administering it immediately also eliminates gaps in protection that occur when vaccination is delayed because of missed visits, social barriers, or unrecognized maternal infection. In addition, newborns respond well immunologically to the recombinant vaccine antigen, and early dosing has been shown to dramatically reduce perinatal and early-childhood HBV transmission rates worldwide. For these reasons—high transmission efficiency at birth, the severe lifelong consequences of chronic infection, the unreliability of maternal screening alone, and the proven effectiveness of early immunization—the hepatitis B birth dose remains an essential, evidence-based intervention to protect infants and prevent future liver disease.

The American College of Obstetricians and Gynecologists (ACOG), supports universal hepatitis B vaccination for all newborns, recommending that the first dose of the hepatitis B vaccine be administered within 24 hours of birth, regardless of the mother’s hepatitis B surface antigen (HBsAg) status. This policy aligns with guidance from The World Health Organization (WHO) who also requires that all infants receive a birth dose of the hepatitis B vaccine as soon as possible after birth, ideally within the first 24 hours of life, regardless of the mother’s hepatitis B status. (ACOG) emphasizes that administering the birth dose serves as a critical safety net, particularly in cases of unrecognized maternal infection, testing errors, or delayed prenatal care. For infants born to mothers who are known to be HBsAg-positive or whose status is unknown at delivery, ACOG recommends both the hepatitis B vaccine and hepatitis B immune globulin (HBIG) within 12 hours of birth. Overall, ACOG views the birth dose as a cornerstone of hepatitis B prevention and a key public health measure to reduce long-term liver disease, including cirrhosis and hepatocellular carcinoma.